After a recent recovery, the Cochlear Limited (ASX: COH) share price has been a mild pleaser for investors. Although Cochlear shares ended the day down by 0.16% at $224.79, the hearing technology company is now up around 1% in 2022 so far, as well as up 3.4% over the past 12 months.
Over the past month, this ASX 200 healthcare share has gained a healthy 4.5%. Saying that, the company is still more than 12% below the all-time high of $257.76 that we saw back in August last year.
Cochlear’s most recent earnings report seems to have been well received by investors too. Back in February, the company announced a 10% increase in sales revenue and a 26% rise in underlying profits to $158 million. Pleasingly for income investors, Cochlear also announced a 35% increase to its interim dividend to $1.55 per share. This saw investors give the Cochlear share price a boost at the time.
But now that we’ve passed the first quarter of 2022, what might be next for Cochlear? What does April hold for this famous brand in the medical space?
Is the Cochlear share price a buy in April?
Well, one ASX broker who is bullish on the Cochlear share price is Morgans. As my Fool colleague James covered last month, Morgans recently upgraded its rating on Cochlear to an ‘add’, with a 12-month share price target of $233.20. If that turns out to be accurate, it would mean Cochlear has a 3.7% or so upside left in the tank over the next year.
Here’s some of what Morgans said on its buy recommendation:
“Cochlear maintains a dominant position in the implantable hearing solutions segment. While we continue to believe a full recovery from Covid-based disruptions still has time to play out, improving demand and strong pipeline, coupled with management’s increasing confidence, is all suggestive of an improving earnings profile.”
So that’s pretty emphatic from one of the ASX’s top brokers.
But we’ll have to wait and see if its bullishness is justified over the next 12 months.
In the meantime, the current Cochlear share price gives this ASX 200 healthcare company a market capitalisation of $14.81 billion, with a dividend yield of 0.92%.
The post What’s the outlook for the Cochlear share price in April? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Cochlear right now?
Before you consider Cochlear, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Cochlear wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- Here are the 3 most heavily traded ASX 200 shares on Thursday
- ASX 200 midday update: Magellan jumps, tech shares tumble
- 3 more of the ‘best’ ASX 200 shares to buy this month: Morgans
- 2 ASX tech shares that are cheap enough to buy now
- 5 things to watch on the ASX 200 on Thursday
Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/A5EYtDj
Leave a Reply